CMVLF (Cellectis) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMVLF Cellectis SA CMVLF
56 GF Score
Price $3.47
GF Value $3.43
! 4 Warning Signs
View Full Analysis

What is Cellectis Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis  (OTCPK:CMVLF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cellectis Cyclically Adjusted PB Ratio Related Terms


Cellectis Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cellectis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Cyclically Adjusted PB Ratio Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 0.31 0.43 0.22 0.72

Cellectis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.38 0.67 0.48 0.56

CMVLF vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PB Ratio falls into.


CMVLF
56GF Score
Cellectis SA CMVLF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cellectis's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cellectis's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.408/123.5000*123.5000
=0.408

Current CPI (Jun. 2026) = 123.5000.

Cellectis Quarterly Data

Book Value per Share CPI Adj_Book
201609 8.112 100.340 9.984
201612 7.778 100.650 9.544
201703 7.686 101.170 9.382
201706 7.547 101.320 9.199
201709 8.354 101.330 10.182
201712 7.952 101.850 9.642
201803 7.674 102.750 9.224
201806 11.527 103.370 13.772
201809 11.108 103.560 13.247
201812 10.612 103.470 12.666
201903 10.189 103.890 12.112
201906 9.544 104.580 11.271
201909 8.994 104.500 10.629
201912 8.371 104.980 9.848
202003 8.727 104.590 10.305
202006 8.122 104.790 9.572
202009 7.678 104.550 9.070
202012 7.219 104.960 8.494
202103 6.732 105.750 7.862
202106 6.650 106.340 7.723
202109 5.765 106.810 6.666
202112 5.199 107.850 5.953
202203 4.464 110.490 4.990
202206 3.967 112.550 4.353
202209 3.196 112.740 3.501
202212 2.757 114.160 2.983
202303 2.168 116.790 2.293
202306 1.737 117.650 1.823
202309 1.370 118.260 1.431
202312 1.180 118.390 1.231
202403 1.262 119.470 1.305
202406 1.485 120.200 1.526
202409 1.293 119.560 1.336
202412 1.309 119.950 1.348
202503 1.159 120.380 1.189
202506 0.968 121.360 0.985
202509 1.002 120.950 1.023
202512 0.756 120.890 0.772
202603 0.596 122.410 0.601
202606 0.408 123.500 0.408

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.47 is trading 1.2% above its estimated GF Value™ of $3.43.

Key valuation signals for CMVLF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $3.43 vs. price of $3.47 (1.2% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
56GF Score

Get the complete analysis for CMVLF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.43
GF Value